191 related articles for article (PubMed ID: 18182343)
41. Salvage therapy for ovarian cancer.
Sabbatini P; Spriggs D
Oncology (Williston Park); 1998 Jun; 12(6):833-43; discussion 844-6, 848, 851. PubMed ID: 9644684
[TBL] [Abstract][Full Text] [Related]
42. Emerging therapeutic options for platinum-sensitive ovarian cancer patients.
Armstrong DK; Coleman RL; Penson RT
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 5):1-16. PubMed ID: 21558997
[TBL] [Abstract][Full Text] [Related]
43. Second-line randomized trials in epithelial ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2008; 18 Suppl 1():59-66. PubMed ID: 18336403
[TBL] [Abstract][Full Text] [Related]
44. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
45. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
[TBL] [Abstract][Full Text] [Related]
46. Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.
Kieback DG; Einzmann T; Labinsky E; Fischer DC; Niebergall H; Hasenburg A
Onkologie; 2004 Aug; 27(4):393-7. PubMed ID: 15347897
[TBL] [Abstract][Full Text] [Related]
47. Clinical application of oxaliplatin in epithelial ovarian cancer.
Fu S; Kavanagh JJ; Hu W; Bast RC
Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
[TBL] [Abstract][Full Text] [Related]
48. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E; Banerjee S; Pignata S
J Clin Oncol; 2019 Sep; 37(27):2437-2448. PubMed ID: 31403868
[No Abstract] [Full Text] [Related]
49. Treatment of platinum-resistant ovarian cancer.
Trimble EL; Wright J; Christian MC
Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998
[TBL] [Abstract][Full Text] [Related]
50. Second-line treatment of ovarian cancer.
Markman M; Bookman MA
Oncologist; 2000; 5(1):26-35. PubMed ID: 10706647
[TBL] [Abstract][Full Text] [Related]
51. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
Jabłońska E; Chłosta M; Pawlega J
Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
53. Management of treatment-related toxicity in advanced ovarian cancer.
Dunton CJ
Oncologist; 2002; 7 Suppl 5():11-9. PubMed ID: 12324629
[TBL] [Abstract][Full Text] [Related]
54. Maintenance chemotherapy in the management of epithelial ovarian cancer.
Markman M
Cancer Metastasis Rev; 2015 Mar; 34(1):11-7. PubMed ID: 25566684
[TBL] [Abstract][Full Text] [Related]
55. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
Baumann KH; Wagner U; du Bois A
Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
[TBL] [Abstract][Full Text] [Related]
56. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
Sessa C; Del Conte G
Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
[No Abstract] [Full Text] [Related]
57. Future directions in the management of epithelial ovarian cancer.
Blagden S; Gabra H
Future Oncol; 2008 Jun; 4(3):403-11. PubMed ID: 18518765
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
[TBL] [Abstract][Full Text] [Related]
59. Epithelial Ovarian Cancer and Cancer Stem Cells.
Soliman AA; Elzarkaa AA; Malik E
Adv Exp Med Biol; 2021; 1330():21-32. PubMed ID: 34339028
[TBL] [Abstract][Full Text] [Related]
60. Recurrent ovarian cancer.
Tummala MK; McGuire WP
Clin Adv Hematol Oncol; 2005 Sep; 3(9):723-36. PubMed ID: 16224447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
